Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POWER: Ustekinumab IV Re-induction in Crohn's Disease
NCT03782376Phase 3Completed
- Sponsor
- Janssen-Cilag
- Start
- Dec 2018
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of ustekinumab in Crohn's disease, sponsored by Janssen-Cilag. Started Dec 2018; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03782376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03782376.